Login / Signup

Proposed response parameters for 12 months drug trial in Juvenile Systemic Sclerosis. Results of the Hamburg International Consensus Meetings.

Ivan FoeldvariKathryn S TorokJens KlotscheJordi AntónPatricia Cost ReisFrancesco Del GaldoChristopher P DentonBernd HinrichsSuzanne C LiClare PainClarissa PilkingtonMaurizio CutoloOzgur KasapcopurZsuzsanna H McMahanNicolino RupertoVanessa SmithDaniel E Furst
Published in: Arthritis care & research (2023)
We reached consensus on multiple domains and items which should be assessed in an open label 12-month clinical jSSc trial as well as a research agenda for future development. This article is protected by copyright. All rights reserved.
Keyphrases
  • systemic sclerosis
  • interstitial lung disease
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • clinical practice
  • rheumatoid arthritis
  • current status
  • public health
  • global health
  • drug induced